Ipamorelin 5mg / 10mg — 45 Sprays

Scientific identity

Ipamorelin (CAS 170851-70-4), also designated NNC 26-0161, is a synthetic five-residue growth hormone secretagogue and selective GHSR-1a agonist. Its molecular formula is C₃₈H₄₉N₉O₅ and its molecular weight is approximately 711.87 g/mol.

Compound class

Synthetic five-residue compound; growth hormone secretagogue (GHS); GHSR-1a agonist. Ipamorelin is classified as a Research Use Only material and is not a drug, dietary supplement, food, or cosmetic.

Sequence

Aib–His–D-2-Nal–D-Phe–Lys–NH₂. The sequence incorporates alpha-aminoisobutyric acid (Aib) at the N-terminus, D-2-naphthylalanine at position 3, D-phenylalanine at position 4, and a C-terminal primary amide. These non-standard structural features distinguish Ipamorelin from naturally occurring biological sequences and are relevant to its receptor engagement and stability properties in experimental systems.

Primary molecular target

Growth hormone secretagogue receptor type 1a (GHSR-1a) — a Class A G protein-coupled receptor, also referred to as the ghrelin receptor.

Distinction from related compounds

Ipamorelin is structurally and pharmacologically distinct from growth hormone, GHRH, ghrelin, GHRP-2, and GHRP-6. These compounds share overlapping biology but have different molecular identities, sequences, and receptor pharmacological profiles. Evidence from one should not be attributed to another without explicit qualification.

Product content

Available in two variants: 5mg per bottle and 10mg per bottle; 45 sprays per bottle for both variants.

Physical form

Liquid research spray.

Purity. Research-grade. Researchers are encouraged to review available analytical documentation prior to incorporating this compound into laboratory workflows.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification

Research Use Only. Not approved for human or veterinary use. Not intended for administration to humans or animals.

Receptor biology: GHSR-1a. Ipamorelin's primary pharmacological target is GHSR-1a, a Class A G protein-coupled receptor encoded by the GHSR gene. GHSR-1a is expressed prominently in pituitary somatotroph cells and in hypothalamic nuclei including the arcuate nucleus, with additional expression reported in several other brain regions and peripheral tissues. The receptor couples primarily to Gq/11 proteins, activating phospholipase C, generating IP3 and DAG, and triggering intracellular calcium mobilization — a signaling cascade associated with GH secretory granule exocytosis in somatotroph cell models. GHSR-1a also exhibits substantial constitutive activity, estimated in some receptor pharmacology studies at approximately 50% of maximal activation, a property that has relevance for interpreting agonist studies using compounds such as Ipamorelin.

Comparative pharmacological profile

A significant focus of published Ipamorelin research has been its comparative pharmacological selectivity relative to earlier growth hormone secretagogue compounds. Foundational characterization by Raun et al. (1998) in rat models reported that Ipamorelin stimulated GH release through GHSR-1a while producing less ACTH and cortisol co-stimulation than GHRP-6 and GHRP-2 in those specific experimental conditions. These findings are from preclinical animal model contexts and establish a comparative pharmacological profile for research purposes — they do not constitute evidence of therapeutic selectivity in humans or clinical superiority over other GHS research compounds for any application. Selectivity in receptor pharmacology is always relative and system-dependent; researchers should consult the primary literature for the specific conditions under which Ipamorelin's profile has been characterized.

Growth hormone axis context

Research on Ipamorelin is situated within the broader scientific context of GH axis regulation, which involves GHRH-mediated stimulation and somatostatin-mediated inhibition of GH release from the pituitary, with GH subsequently stimulating hepatic IGF-1 production through GH receptor signaling. Ipamorelin has been studied as a pharmacological probe for GHSR-1a biology within this axis. Experimental data on GH secretory responses following Ipamorelin in animal models provide pharmacodynamic information about GHSR-1a-mediated signaling in those systems; they do not establish downstream IGF-1 changes or any consumer outcome as a result of this product.

Key research areas

Published research involving Ipamorelin spans GHSR-1a receptor pharmacology, comparative growth hormone secretagogue biology, pituitary somatotroph signaling, endocrine and neuroendocrine research, and structure-activity relationship studies. The compound has also been examined in early-phase human clinical pharmacology investigations characterizing pharmacodynamic GH responses, though Ipamorelin is not approved for any human therapeutic indication and this product is supplied strictly for laboratory research use. All findings referenced here are from experimental research contexts and do not establish human efficacy or safety.

Quality in synthetic GHS pentapeptide research material requires analytical attention to the specific structural features that define Ipamorelin's molecular identity and experimental utility. Several features of Ipamorelin's structure make analytical identity confirmation particularly important:

Sequence identity and non-standard residue verification: The presence of alpha-aminoisobutyric acid (Aib) at the N-terminus, D-2-naphthylalanine at position 3, and D-phenylalanine at position 4 means that Ipamorelin's sequence cannot be confirmed by standard protein sequencing methods designed for L-amino acid sequences. Analytical approaches capable of distinguishing Aib from L-alanine, D-amino acid residues from their L-counterparts, and D-2-naphthylalanine from related aromatic residues are therefore relevant to sequence identity verification for this compound.

Mass spectrometric identity confirmation: Mass spectrometry provides the primary analytical tool for confirming the molecular weight of Ipamorelin (~711.87 g/mol, formula C₃₈H₄₉N₉O₅) and distinguishing the intact compound from truncated sequences, deletion products, and synthesis-related impurities. Electrospray ionization mass spectrometry generating [M+H]⁺ and [M+2H]²⁺ ions provides identification-level molecular weight confirmation appropriate for a compound of this size.

Aib-containing peptide stability: The presence of the Aib N-terminal residue contributes to metabolic stability by providing resistance to aminopeptidase degradation, but Ipamorelin may still be subject to other degradation pathways in solution. Researchers evaluating the suitability of this preparation for biological assays should consider whether available documentation addresses solution stability under the intended experimental conditions.

Chromatographic purity assessment: High-performance liquid chromatography under reversed-phase conditions provides quantitative purity assessment, separating Ipamorelin from co-eluting impurities and enabling characterization of the purity profile at the batch level. Combined HPLC and mass spectrometric data provide the analytical basis for confident research-grade use.

D-amino acid stereochemical integrity: The D-configured residues in Ipamorelin (D-2-Nal at position 3 and D-Phe at position 4) are essential to the compound's GHSR-1a pharmacological profile. Epimerization of these D-amino acid residues — yielding the corresponding L-configuration — could produce a compound with different receptor properties. Analytical approaches sensitive to stereochemical integrity, such as chiral HPLC or stereoselective mass spectrometric fragmentation, represent relevant quality considerations for this class of synthetic peptide.

Batch traceability: Linking experimental results to a defined, analytically characterized batch is a prerequisite for reproducible research. Batch-specific documentation supports data integrity and compliance with institutional requirements governing research chemical use.

Longevia Research is committed to supplying research compounds that support rigorous scientific inquiry. Researchers are encouraged to review available analytical documentation for this product prior to incorporating it into laboratory workflows.

Ipamorelin 5mg / 10mg — 45 Sprays is supplied by Longevia Research strictly for research and laboratory use only. This product is not approved by the FDA or any global regulatory authority for human consumption, veterinary use, or therapeutic application. It is not a drug, dietary supplement, food, or cosmetic, and it is not manufactured, labeled, or sold as any of these under any applicable regulatory framework.

Ipamorelin is a synthetic pentapeptide and GHSR-1a agonist and should not be equated with growth hormone, GHRH, ghrelin, IGF-1, GHRP-2, GHRP-6, or other compounds. Research findings, pharmacological characterizations, and clinical pharmacology studies involving other growth hormone secretagogues, pharmaceutical growth hormone preparations, or the broader GH/IGF-1 axis do not automatically establish the safety, efficacy, pharmacokinetics, or appropriate use of this specific Longevia Research Ipamorelin spray product.

No claims made regarding Ipamorelin on this website are intended to diagnose, treat, cure, or prevent any disease or medical condition in humans or animals. The research findings summarized on this page arise from receptor pharmacology studies, pituitary cell and tissue experiments, preclinical animal pharmacology research, and early-phase clinical pharmacology investigations. These findings do not establish human therapeutic efficacy or safety for any application — including muscle growth, athletic performance, fat loss, recovery, sleep improvement, anti-aging, or any other consumer or therapeutic outcome — and they do not constitute regulatory approval, clinical validation, or authorization for personal or therapeutic use.

This product is sold exclusively to qualified researchers, laboratories, and scientific institutions for in-vitro and non-clinical laboratory research purposes. It is not intended for personal use, self-administration, resale for human consumption, or any application outside of a controlled research environment. Purchasers are responsible for ensuring that the acquisition, possession, handling, storage, use, and disposal of this compound are conducted in full compliance with all applicable local, state, federal, and international laws and institutional policies governing research chemicals.

By purchasing Ipamorelin from Longevia Research, the buyer confirms they are acquiring the product for legitimate scientific research purposes, agrees to handle and store it in accordance with applicable laboratory safety standards, and assumes full responsibility for compliance with all laws and regulations governing the purchase and use of research chemicals in their jurisdiction.